Brokers Set Expectations for Theratechnologies Inc.’s FY2018 Earnings (TH)

Theratechnologies Inc. (TSE:TH) – Investment analysts at National Bank Financial cut their FY2018 EPS estimates for shares of Theratechnologies in a report issued on Tuesday. National Bank Financial analyst E. Leno now anticipates that the company will post earnings of $0.14 per share for the year, down from their previous estimate of $0.35. National Bank Financial has a “Outperform” rating and a $8.75 price target on the stock.

Separately, Scotiabank dropped their price target on Theratechnologies from C$10.00 to C$9.25 and set an “outperform” rating for the company in a research report on Friday, October 6th.

TRADEMARK VIOLATION NOTICE: This story was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.com-unik.info/2017/11/18/brokers-set-expectations-for-theratechnologies-inc-s-fy2018-earnings-th.html.

Theratechnologies (TSE TH) opened at C$6.43 on Friday. Theratechnologies has a 52 week low of C$2.61 and a 52 week high of C$8.72.

Theratechnologies Company Profile

Theratechnologies Inc is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy.

Earnings History and Estimates for Theratechnologies (TSE:TH)

What are top analysts saying about Theratechnologies Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Theratechnologies Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit